share_log

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A:超過5%持股股東披露文件(修正)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)
美股SEC公告 ·  2024/08/15 17:27

Moomoo AI 已提取核心訊息

On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.
On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.
2024年4月12日,醫療器械公司t2 biosystems成爲證交會提交的13G文件的主題,表明所有權發生了變化。該提交揭示了總部位於開曼群島的新維度貿易有限公司和美國公民Jacob Safier共同報告擁有755,000股t2 biosystems普通股,這代表公司證券類別的4.3%。提交中報告的股票基於t2 biosystems根據最新季度報告於2024年8月8日提交的17,479,954股普通股。該提交由New Dimensions Trading Ltd.的董事Chana Edelstein和Jacob Safier簽署,宣稱收購股票的目的不是爲了更改或影響t2 biosystems的控制,也不與任何具有此目的或效果的交易相關。
2024年4月12日,醫療器械公司t2 biosystems成爲證交會提交的13G文件的主題,表明所有權發生了變化。該提交揭示了總部位於開曼群島的新維度貿易有限公司和美國公民Jacob Safier共同報告擁有755,000股t2 biosystems普通股,這代表公司證券類別的4.3%。提交中報告的股票基於t2 biosystems根據最新季度報告於2024年8月8日提交的17,479,954股普通股。該提交由New Dimensions Trading Ltd.的董事Chana Edelstein和Jacob Safier簽署,宣稱收購股票的目的不是爲了更改或影響t2 biosystems的控制,也不與任何具有此目的或效果的交易相關。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息